B&K CORPORATION LIMITED 華芢生物科技（青島）股份有限公司 （以下稱「公司」） 內控委員會議事規則 第一章 總則 第一條 為強化華芢生物科技（青島）股份有限公司（下稱「公司」）董事會職 能，健全公司內部控制制度，完善公司內部控制程序和公司治理結構，根據《中 華人民共和國公司法》《華芢生物科技（青島）股份有限公司章程》（下稱「《公司 章程》」）及其他有關規定，公司特設立董事會內控委員會，並制定本規則。 第二條 董事會內控委員會是董事會按照股東大會決議設立的專門工作機 構，主要負責監督和檢查內部控制情況，為董事會提供諮詢意見，向董事會報 告工作。 第二章 人員組成 第三條 內控委員會成員由公司董事長和全體獨立董事組成。 （於中華人民共和國成立的股份有限公司） （股份代號：2396） 第七條 內控委員會對董事會負責，委員會的提案提交董事會審議決定。 第四條 內控委員會設主任委員（召集人）一名，由公司董事長擔任，負責 主持委員會工作。 第五條 內控委員會任期與董事會任期一致，委員任期屆滿，連選可以連 任。期間如有委員不再擔任公司董事職務，自動失去委員資格，並由委員會根 據上述第三條規定補足委員人 ...

B&K CORPORATION LIMITED 華芢生物科技（青島）股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2396） （以下稱「公司」） 提名委員會 — 職權範圍書 1. 成員 2. 秘書 5.1 提名委員會主席或（如其缺席）提名委員會之其他一名成員（必須為獨立非 執行董事）需出席本公司股東週年大會，並響應股東就提名委員會活動等 責任作出之提問。 – 2 – 3.3 提名委員會會議所需之法定人數為任何兩名提名委員會成員，其中至少 一名成員須為獨立非執行董事。 3.4 會議可以親身出席、採用電話或視像會議之方式舉行。提名委員會成員可 透過會議電話或類似通訊設備（所有參與會議之人士均能夠透過該設備聆 聽對方）參與會議。 3.5 提名委員會之決議案，如於會議上作出決議，須以出席會議的過半數提名 委員會成員投票通過。倘出現票數相同的情況，提名委員會主席可投第二 票或決定票。 3.6 由提名委員會全體成員書面簽署之決議案亦為有效，猶如其已於提名委 員會正式召開及舉行會議上獲通過一樣。 3.7 提名委員會的完整會議紀錄應由正式委任的會議秘書保存，以供各董事 審閱。會議紀錄草稿及最終定稿應在會議 ...

B&K CORPORATION LIMITED 薪酬委員會 — 職權範圍書 1. 成員 2. 秘書 – 1 – 華芢生物科技（青島）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2396） （以下稱「公司」） 薪酬委員會須具有下列責任及權力： 1.1 薪酬委員會由公司董事會設立，且薪酬委員會須由最少三名成員組成，其 大多數成員應為獨立非執行董事。薪酬委員會成員由董事會委任。 1.2 薪酬委員會主席由董事會委任，並須為獨立非執行董事。 1.3 薪酬委員會成員的委任年期由董事會於委任時決定，最長不得超過該成 員的董事任期。 2.1 薪酬委員會之秘書由公司秘書擔任。 2.2 薪酬委員會可不時委任其他任何具備合資格及經驗之人士為薪酬委員會 之秘書。 3. 會議 – 2 – 3.1 薪酬委員會每年最少須舉行一次會議。薪酬委員會任何成員或秘書可要 求舉行會議。 3.2 任何會議之通知最少須於該會議舉行前5個工作日（週六、週日及中國內 地和香港的公眾假期除外）作出，除非全體成員一致通過豁免該通知。儘 管有通知期，薪酬委員會成員出席會議將被視為該成員豁免所需之通知期。 倘續會於會議後14天內舉行，則任 ...

華芢生物科技（青島）股份有限公司 章 程 （首次公開發行H股後適用） | 第一章 | 總則 | 1 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 3 | | 第三章 | 股份和註冊資本 | 4 | | 第一節 | 股份發行 | 4 | | 第二節 | 股份的增減和回購 | 6 | | 第三節 | 股份轉讓 | 8 | | 第四章 | 股東和股東大會 | 10 | | 第一節 | 股東 | 10 | | 第二節 | 股東大會的一般規定 | 14 | | 第三節 | 股東大會的召集 | 18 | | 第四節 | 股東大會的提案與通知 | 20 | | 第五節 | 股東大會的召開 | 23 | | 第六節 | 股東大會的表決和決議 | 27 | | 第五章 | 董事會 | 34 | | 第一節 | 董事 | 34 | | 第二節 | 董事會 | 41 | | 第三節 | 專門委員會 | 48 | | 第六章 | 總經理及其他高級管理人員 | 48 | | 第七章 | 監事會 | 51 | | 第一節 | 監事 | 51 | | 第二節 | 監事會 | 53 | | 第八章 | 財務 ...

審核委員會 — 職權範圍書 B&K CORPORATION LIMITED 華芢生物科技（青島）股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2396） （以下稱「公司」） 2.1 審核委員會之秘書由公司秘書擔任。 2.2 審核委員會可不時委任其他任何具備合適資格及經驗之人士為審核委員 會之秘書。 3. 會議 – 2 – 3.1 審核委員會每年最少須舉行兩次會議。審核委員會任何成員或秘書可要 求舉行會議。公司之外聘核數師如認為有需要，可要求舉行會議。 3.2 任何會議之通知最少須於該會議舉行前5個工作日（週六、週日及中國內 地和香港的公眾假期除外）發出，除非審核委員會全體成員一致通過豁免 該通知。儘管有通知期，審核委員會成員出席會議將被視為該成員豁免所 需之通知期。倘續會於會議後14天內舉行，則任何續會毋須發出通知。 3.3 審核委員會會議所需之法定人數為任何兩名審核委員會成員，其中至少 一名成員須為獨立非執行董事。 3.4 會議可以親身出席、採用電話或視像會議之方式舉行。審核委員會成員可 透過會議電話或類似通訊設備（所有參與會議之人士均能夠透過該設備聆 聽對方）參與會議。 3.5 審核委 ...

Core Viewpoint - Huazhong Biopharmaceutical Company-B (02396) has successfully completed its IPO subscription, raising significant interest with an oversubscription rate of 594 times the public offering amount of HKD 90.02 million [1] Group 1: IPO Details - The IPO subscription period was from December 12 to December 17, with a total of HKD 53.6 billion in margin financing from brokers [1] - The company plans to issue 17.6488 million H-shares, with approximately 10% allocated for public offering and 90% for international offering, along with a 15% over-allotment option [1] - The share price is set between HKD 38.2 and HKD 51, with a minimum investment of HKD 10,302.9 for one lot of 200 shares, aiming to raise up to HKD 900 million [1] Group 2: Company Overview - Established in 2012, Huazhong Biopharmaceutical focuses on developing protein drugs for various therapeutic areas, particularly in wound healing therapies [1] - The company has two core products in its pipeline: Pro-101-1 for treating deep second-degree burns, which has completed IIb clinical trials, and Pro-101-2 for diabetic foot ulcers, currently in II phase clinical trials [2] Group 3: Market Position and Financials - As of the latest date, there are no approved PDGF products in the Chinese biopharmaceutical market, with Huazhong holding two of the three PDGF drug pipelines in the country [3] - The company has not yet commercialized any of its candidate products and has not generated any revenue from sales [3] - Financially, Huazhong reported net losses of RMB 105 million, RMB 212 million, and RMB 135 million for the fiscal years ending September 30 for 2023, 2024, and 2025, respectively, primarily due to R&D and administrative expenses [3] Group 4: Use of Proceeds - Approximately 61.8% of the net proceeds from the global offering will be allocated to the continued clinical development and commercialization of core products Pro-101-1 and Pro-101-2 [4] - About 18.8% will be used to enhance R&D capabilities through the purchase of specialized equipment and instruments [4] - The remaining proceeds will fund ongoing preclinical research for other PDGF products and operational expenses [4]

Core Insights - Huazhang Biopharmaceutical Company (华芢生物-B) has successfully completed its IPO subscription, raising HKD 900.2 million with an oversubscription rate of 594 times [1] - The company plans to issue 17.6488 million H-shares, with approximately 10% allocated for public offering and 90% for international placement, and expects to list on December 22 [1] Company Overview - Established in 2012, Huazhang Biopharmaceutical focuses on developing protein drugs for various therapeutic indications, particularly in wound healing therapies [1] - The company is currently developing two core products: Pro-101-1 for deep second-degree burns and Pro-101-2 for diabetic foot ulcers, with both in different stages of clinical trials [2] Clinical Development - Pro-101-1 has completed the statistical analysis of its Phase IIb clinical trial, while Pro-101-2 is in Phase II, but the enrollment progress has been slow since February 2022 [2] - There are concerns regarding the statistical significance of the clinical trial data for Pro-101-1, indicating potential challenges in proving its efficacy [2] Market Position - As of the latest date, there are no approved PDGF products in the Chinese biopharmaceutical market, with Huazhang Biopharmaceutical holding two of the three PDGF drug pipelines in the country [3] - The company aims to commercialize at least two innovative drugs within the next six years, utilizing a direct sales team and strategic partnerships for market coverage [3] Financial Performance - The company has reported net losses for the past years, with losses of RMB 105 million, RMB 212 million, and RMB 135 million for the fiscal years ending September 30, 2023, 2024, and 2025 respectively, primarily due to R&D and administrative expenses [3] Use of Proceeds - Approximately 61.8% of the net proceeds from the global offering will be allocated to the continued clinical development and commercialization of core products Pro-101-1 and Pro-101-2 [4] - Other allocations include 18.8% for enhancing R&D capabilities through equipment purchases, 6.3% for preclinical development of other PDGF products, and 10% for working capital and general corporate purposes [4]

Group 1: Company Overview - Huaman Biotechnology Co., Ltd. - B is a biopharmaceutical company established in 2012, focusing on developing protein drugs for wound healing therapies [4] - Nanhua Futures Co., Ltd. is one of the first companies in China's futures industry, providing global financial services and ranked eighth among all futures companies in China by total revenue in 2024 [9] - Impression Dahongpao Co., Ltd. is a state-owned cultural tourism service enterprise based in Wuyishan, Fujian Province, with operations in performance services, cultural tourism town business, and tea hotel business [21] Group 2: IPO Details - Huaman Biotechnology plans to issue 17.6488 million H-shares with a price range of HKD 38.20-51.00, and the subscription period is from December 12 to December 17, 2025 [2] - Nanhua Futures plans to issue 108 million H-shares with a price range of HKD 12.00-16.00, and the subscription period is also from December 12 to December 17, 2025 [7] - Impression Dahongpao plans to issue 36.1 million H-shares with a price range of HKD 3.47-4.10, with the same subscription period [19] Group 3: Financial Performance - Huaman Biotechnology reported revenues of RMB 471,700 in 2023 and net losses of RMB 1.0519 billion, RMB 2.1225 billion, and RMB 1.6410 billion for the years 2023, 2024, and the nine months ending September 30, 2025, respectively [6] - Nanhua Futures reported revenues of RMB 954.41 million, RMB 1.29287 billion, and RMB 1.35484 billion for the years 2022, 2023, and 2024, with profits increasing from RMB 245.91 million in 2022 to RMB 402.82 million in 2023 [12] - Impression Dahongpao's revenues were approximately RMB 63.04 million, RMB 143.89 million, and RMB 137.20 million for the years 2022, 2023, and 2024, with net profits of RMB 47.50 million in 2023 [23]

Group 1 - The company plans to globally offer 17.6488 million shares, with 1.765 million shares available in Hong Kong and 15.8838 million shares for international sale, along with an over-allotment option of 2.6472 million shares [1] - The subscription period is set from December 12 to December 17, with a maximum offer price of HKD 51.00 per share and an entry fee of approximately HKD 10,302.88 for 200 shares [1] - The total expected fundraising amount is HKD 787 million, with a net amount of HKD 709 million, which will be used for the clinical development and commercialization of core products Pro101-1 and Pro-101-2, enhancing R&D capabilities, and general corporate purposes [1] Group 2 - The company’s main business includes technology services, medical device sales, cosmetics wholesale and retail, and medical research and development [2] - The net profits for the years 2023, 2024, and the first three quarters of 2025 (ending September 30) are projected to be -CNY 105 million, -CNY 212 million, and -CNY 134 million, reflecting year-on-year changes of -22.42%, -101.78%, and 18.06% respectively [2]

B&K CORPORATION LIMITED 華芢生物科技(青島)股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 股份代號 : 2396 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 B&K CORPORATIO N LIMITE D 青 島)股 份有限公 司 B&K CORPORATION LIMITED 華芢生物科技(青島)股份有限公司 全球發售 C M Y CM MY CY CMY K ai1765375134714_Project Sunflower Cover V09D_31mm_OP_C.pdf 1 10/12/2025 下午9:58 華芢生物科技( 重要提示 閣下對本招股章程任何內容如有任何疑問，應徵詢獨立專業意見。 B&K CORPORATION LIMITED 華芢生物科技（青島）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售項下的發售股份數目 | ： | 17,648,800股H股股份（視乎超額配股權行使與否 | | --- | --- | --- | | 而 ...